RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease

International Journal of Molecular Medicine

Volumn 22, Issue 1, 2008, Pages 25-31

  Bellizzi, Antonia ^a   Mangia, Anita ^a   Chiriatti, Annalisa ^a   Petroni, Stella ^a   Quaranta, Michele ^a   Schittulli, Francesco ^a   Malfettone, Andrea ^a   Cardone, Rosa Angela ^b   Paradiso, Angelo ^a   Reshkin, Stephan Joel ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Lymphocytes; Prognosis; Progression; RhoA

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STEROID RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CELL ISOLATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; AGED; BREAST TUMOR; DISEASE COURSE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY;

AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; RHOA GTP-BINDING PROTEIN; STATISTICS, NONPARAMETRIC;

EID: 52049085776     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.22.1.25     Document Type: Article

References (50)

1. Lin M and van Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 84: 49-60, 2004.
2. Olson MF, Ashworth A and Hall A: An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269: 1270-1272, 1995.
3. Worthylake RA, Lemoine S, Watson JM and Burridge K: RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154: 147-160, 2001.
4. Adamson P, Etienne S, Couraud PO, Calder V and Greenwood J: Lymphocyte migration through brain endothelial cell monolayers involves signalling through endothelial ICAM-1 via Rho-dependent pathway. J Immunol 162: 2964-2973, 1999.
5. Paradiso A, Cardone RA, Bellizzi A, Bagorda A, Guerra L, Tommasino M, Casavola V and Reshkin SJ: The Na+-H+ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. Breast Cancer Res 6: R616-R628, 2004.
6. Li B, Zhao WD, Tan ZM, Fang WG, Zhu L and Chen YH: Involvement of Rho/ ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 580: 4252-4260,2006.
7. Kelly P, Stemmle LN, Madden JF, Fields TA, Daaka Y and Casey PJ: A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 281: 26483-26490, 2006.
8. Kusama T, Mukai M, Endo H, Ishikawa O, Tatsuta M, Nakamura H and Inoue M: Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci 97: 848-853, 2006.
9. Zheng R, Iwase A, Shen R, Goodman OB, Sugimoto N, Takuwa Y, Lerner DJ and Nanus DM: Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 25: 5942-5952, 2006.
10. Kusama T, Mukai M, Tatsuta M, Nakamura H and Inoue M: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol 29: 217-223, 2006.
11. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, Casavola V, Zaccolo M and Reshkin SJ: PKA gating of a pseudopodial located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell 16: 3117-3127, 2005.
12. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83: 861-870, 2003.
13. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima. H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641, 2003.
14. Fukui K, Tamura S, Wada. A, Kamada Y, Sawai Y, Imanaka K, Kudara T, Shimomura I and Hayashi N: Expression and prognostic role of RhoA GTPases In hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 627-633, 2006.
15. Li XR, Ji F, Ouyang J, Wu W, Qian LY and Yang KY: Over-expression of RhoA is associated with poor prognosis in hepato-cellular carcinoma. Eur J Surg Oncol 32: 1130-1134, 2006.
16. Faried A, Nakajima M, Sohda M, Miyazaki T, Kato H and Kuwano H: Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma. Eur J Surg Oncol 31: 410-414, 2005.
17. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H and Hirohashi S: Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33: 577-581, 2001.
18. Van Aelst L and D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 11: 2295-2322, 1997.
19. Kamai T, Arai K, Sumi S, Tsujii T, Honda M, Yamanishi T and Yoshida KI: The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 89: 449-453, 2002.
20. Kamai T, Arai K, Tsujii T, Honda M and Yoshida K: Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell turnout. BJU Int 87: 227-231, 2001.
21. Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687, 1999.
22. Kamai T, Kawakami S, Koga F, Arai G, Takagi K, Arai K, Tsujii T and Yoshida KI: RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 91: 234-238, 2003.
23. Finlayson CA, Chappell J, Leitner JW, Goalstone ML, Garrity M, Nawaz S, Ciaraldi TP and Draznin B: Enhanced insulin signaling via Shc in human breast cancer. Metabolism 52: 1606-1611, 2003.
24. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003.
25. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK and Dorner AJ: Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11: 1181-1189, 2005.
26. Espina V, Dettloff KA, Cowherd S, Petricoin EF III and Liotta LA: Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol ner 4: 83-93, 2004.
27. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G and Kimura S: Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 50: 1015-1020, 1995.
28. Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR and Agarwal A: Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 17: 426-431, 2002.
29. Flores I, Rivera E, Mousses S, Chen Y and Rozenblum E: Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarrays. Fertil Steril 85: 1676-1683, 2006.
30. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT and Tooney PA: Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82: 175-183, 2006.
31. Hoser G, Domagata-Kulawlk J, Droszcz P, Droszcz W and Kawiak J: Lymphocytes subset differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 9: BR310-BR315, 2003.
32. Finch CE and Crimmins EM: Inflammatory exposure and historical changes in human life-spans. Science 305: 1736-1739, 2004.
33. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S and Sirigu P: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33: 420-425, 2003.
34. Imada A, Shijubo N, Kojima H and Abe S: Mast cells correlate with angiogenesis and poor outcome in stage I lung adeno-carcinoma. Eur Respir J 15: 1087-1093, 2000.
35. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 15;56: 4625-4629, 1996.
36. Leek RD, Landers RJ, Harris AL and Lewis CE: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991-995, 1999.
37. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005.
38. De Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37, 2006.
39. Greene FL and Sobin LH: The TNM system: our language for cancer care. J Surg Oncol 80: 119-120, 2002.
40. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41: 151, 2002.
41. Sundquist M, Thorstenson S, Brudin L and Nordenskjold B: Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 53: 1-8, 1999.
42. Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A and Paradiso A: BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res Oct 578: 395-405, 2005.
43. Bourne HR, Sanders DA and McCormick F: The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348: 125-132, 1990.
44. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF and Blamey RW: The prognosis of small primary breast cancers. Eur J Cancer 35: 908-912, 1999.
45. Kollias J. Sibbering DM, Blarney RW, Holland PA, Obuszko Z, Wilson AR, Evans AJ, Ellis IO and Elston CW: Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 34: 878-883, 1998.
46. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW: Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 75: 1318-1323, 1997.
47. Fukui K, Tamura S, Wada A, Kamada Y, Sawai Y, Imanaka K, Kudara T, Shimomura I and Hayashi N: Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 627-633, 2006.
48. Fritz G, Brachetti C, Bahlmann F, Schmidt M and Kaina. B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87: 635-644, 2002.
49. Colburn WA: Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 43: 329-341, 2003.
50. Frank R and Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580, 2003.